First report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this GLP-1/GIP dual agonist with a potential thromboembolic signal.
Key findingFirst report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this
What the researchers found
First report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this GLP-1/GIP dual agonist with a potential thromboembolic signal.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Patient in her early 40s. D-dimer elevated at 1340 ng/mL. CT confirmed right main pulmonary artery PE. Onset 20 days after starting tirzepatide.
How the study worked
In publication.
Who was studied
Single female patient in her early 40s who developed PE after starting tirzepatide
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.
BMJ case reports, 18(7)
Citation
Alsararatee, Hasan H. (2025). Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.. BMJ case reports, 18(7). https://doi.org/10.1136/bcr-2025-266561